BT942 treatment resulted in remarkable increase in CD45+, CD3+, CD8+, CD8+ granzyme B+, CD8+Ki67+, CD4+, CD4+Teff, CD4+Teff granzyme B+ and CD4+Teff Ki67+ T cell percentage in MC38 tumor (Fig. 7b–j). This evidence concerns the gene CD4 and neoplasm.